Does Insurance Cover GLP-1 Medications? A 2026 Coverage Guide

GLP-1 medications sit at an intersection of two conditions—type 2 diabetes and obesity—that insurance companies have historically treated very differently. Diabetes medications are generally covered more consistently; weight loss drugs have faced more resistance.

The result is a patchwork of coverage rules. The same medication might be covered for one patient and denied for another based on their diagnosis code, plan type, or state of residence.

In 2026, the landscape has shifted somewhat, with more insurers recognizing obesity as a chronic disease and expanding coverage—but gaps remain substantial.

If you have type 2 diabetes, GLP-1 medications like Ozempic and Mounjaro have a higher chance of being covered by commercial insurance. These drugs are FDA-approved for diabetes management and are widely included on formularies.

That said, your insurer may still require prior authorization, step therapy (trying cheaper medications first), or proof that other diabetes treatments were insufficient.

Medicare Part D plans typically cover GLP-1s for diabetes, though the specific formulary tier and cost-sharing depend on the plan.

Getting coverage for GLP-1 medications specifically for weight loss is more difficult. Many commercial plans exclude weight loss drugs entirely from their formularies.

Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management and may be covered under plans that include anti-obesity medications—but this is far from universal.

As of 2026, Medicare Part D covers Wegovy and Zepbound for obesity under certain plans, a policy shift that expanded access significantly for Medicare beneficiaries.

The most direct way to check coverage is to call the member services number on your insurance card and ask specifically about coverage for the GLP-1 medication your doctor is prescribing.

You can also check your insurer's formulary (drug list) online—usually available on your insurance portal. Search for the medication name and look at which tier it's on and whether any restrictions apply.

Your doctor's office or a specialty pharmacy can also run a benefits check on your behalf, which often provides more detailed coverage and prior authorization information.

An insurance denial is not necessarily final. You have the right to appeal, and appeals are successful more often than people expect, particularly when a doctor provides documentation supporting medical necessity.

Your prescribing provider can write a letter of medical necessity explaining why the GLP-1 is appropriate for your specific situation. This is often the most effective tool in an appeal.

If an appeal fails, alternative strategies include applying for manufacturer patient assistance programs, switching to a lower-cost alternative, or accessing compounded versions through a telehealth provider.

If your insurance won't cover GLP-1 medications, you're not out of options. Telehealth providers offer bundled programs that include compounded semaglutide or tirzepatide for $150–$500 per month—much less than the retail price of branded versions.

Manufacturer savings cards can help commercially insured patients reduce costs if prior authorization is approved but there's a high copay.

For those with very low income, patient assistance programs from Novo Nordisk and Eli Lilly provide free or heavily discounted medication for eligible applicants.